dc.contributor.author |
Grischke, Eva-Maria |
|
dc.date.accessioned |
2019-04-23T07:03:26Z |
|
dc.date.available |
2019-04-23T07:03:26Z |
|
dc.date.issued |
2017 |
|
dc.identifier.issn |
1569-8041 |
|
dc.identifier.uri |
http://hdl.handle.net/10900/87871 |
|
dc.language.iso |
en |
de_DE |
dc.publisher |
Oxford Univ Press |
de_DE |
dc.relation.uri |
http://dx.doi.org/10.1093/annonc/mdx494 |
de_DE |
dc.rights |
info:eu-repo/semantics/closedAccess |
|
dc.subject.ddc |
610 |
de_DE |
dc.title |
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/- weekly paclitaxel |
de_DE |
dc.type |
Article |
de_DE |
utue.quellen.id |
20190131163842_00594 |
|
utue.publikation.seiten |
2768-2772 |
de_DE |
utue.personen.roh |
Nitz, U. A. |
|
utue.personen.roh |
Gluz, O. |
|
utue.personen.roh |
Christgen, M. |
|
utue.personen.roh |
Grischke, E. -M |
|
utue.personen.roh |
Augustin, D. |
|
utue.personen.roh |
Kuemmel, S. |
|
utue.personen.roh |
Braun, M. |
|
utue.personen.roh |
Potenberg, J. |
|
utue.personen.roh |
Kohls, A. |
|
utue.personen.roh |
Krauss, K. |
|
utue.personen.roh |
Stefek, A. |
|
utue.personen.roh |
Schumacher, C. |
|
utue.personen.roh |
Forstbauer, H. |
|
utue.personen.roh |
Reimer, T. |
|
utue.personen.roh |
Fischer, H. |
|
utue.personen.roh |
Liedtke, C. |
|
utue.personen.roh |
Wuerstlein, R. |
|
utue.personen.roh |
Schumacher, J. |
|
utue.personen.roh |
Kates, R. |
|
utue.personen.roh |
Kreipe, H. |
|
utue.personen.roh |
Harbeck, N. |
|
dcterms.isPartOf.ZSTitelID |
Annals of Oncology |
de_DE |
dcterms.isPartOf.ZS-Issue |
11 |
de_DE |
dcterms.isPartOf.ZS-Volume |
28 |
de_DE |
utue.fakultaet |
04 Medizinische Fakultät |
de_DE |